Paolo Calabrò: Lower LDL-C Variability With PCSK9 Inhibitors and Inclisira
Paolo Calabrò, Director of the Cardiovascular Department at S. Anna and S. Sebastiano Hospital, shared on LinkedIn:
”Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy.”
Title: Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Authors: Arturo Cesaro, Vincenzo Acerbo, Francesco Scialla, Andrea Zito, Gennaro Porcelli, Domenico Panico, Giovanni Argenziano, Demetrio Iaria, Maria Grazia Monaco, Vincenzo De Sio, Felice Gragnano, Michele Golino, Massimiliano Ruscica, Stefano Carugo, Alberto Corsini, Paolo Calabrò
Read the full article here.
Stay updated with Hemostasis Today.
-
Jul 31, 2026, 03:43American Society of Hematology Opens Doors to Hematology Education Worldwide
-
Jul 31, 2026, 03:23Roberta Gualtierotti: Major Genomic Study Identifies Novel Fibromyalgia Risk Genes
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal
-
Jul 30, 2026, 15:162025 Platelet Transfusion Thresholds: When to Transfuse and When Not to Transfuse – Chokri Ben Lamine
-
Jul 30, 2026, 14:34Flora Peyvandi: Genetics of Early-Onset Coronary Artery Disease in Iranians